Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

LATTE

Centre for Cancer Prevention

Project Investigator:  Professor Jack Cuzick

Funding Bodies:  Cancer Research UK and AstraZeneca

Overview

Long-term Anastrozole vs. Tamoxifen Treatment Effects (LATTE) is the post ten-year follow up study of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant trial in postmenopausal women with early breast cancer.

The ATAC trial was a 10 year study designed to compare the efficacy and safety of Anastrozole and Tamoxifen Alone or in Combination, as treatment in post-menopausal women with invasive breast cancer.  There were approximately 9,500 patients included in the trial who received one of the following treatments for 5 years, and then off treatment for the remaining 5 years:

  • Anastrozole + Tamoxifen placebo
  • Tamoxifen + Anastrozole placebo
  • Anastrozole + Tamoxifen

Study Design

LATTE is the long-term follow-up study from the ATAC trial which occured over 10 years ago.  It includes approximately 4,300 post-menopausal women with breast cancer who were randomised to receive either Anastrozole + Tamoxifen placebo or Tamoxifen + Anastrozole placebo in the ATAC trial.

LATTE aims to provide additional efficacy data on breast cancer recurrence, information on survival, new primary cancers, major ischaemic cardiac and cerebrovascular events.

Treatments

There are no trial drugs or treatments associated with this observational study.

 
Return to top